Lowest-Rated StocksLowest-RatedNASDAQ:ISEE IVERIC bio (ISEE) Stock Forecast, Price & News $37.75 +0.03 (+0.08%) (As of 12:34 PM ET) Add Compare Share Share Today's Range$37.46▼$37.8650-Day Range$22.64▼$38.0552-Week Range$8.85▼$38.25Volume1.04 million shsAverage Volume3.17 million shsMarket Capitalization$5.20 billionP/E RatioN/ADividend YieldN/APrice Target$27.45 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media IVERIC bio MarketRank™ ForecastAnalyst RatingHold2.09 Rating ScoreUpside/Downside27.1% Downside$27.45 Price TargetShort InterestBearish8.60% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 8 Articles This WeekInsider TradingSelling Shares$6.75 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.76) to ($1.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.35 out of 5 starsMedical Sector955th out of 1,006 stocksPharmaceutical Preparations Industry472nd out of 492 stocks 2.0 Analyst's Opinion Consensus RatingIVERIC bio has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on 1 buy rating, 10 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.45, IVERIC bio has a forecasted downside of 27.1% from its current price of $37.67.Amount of Analyst CoverageIVERIC bio has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.60% of the outstanding shares of IVERIC bio have been sold short.Short Interest Ratio / Days to CoverIVERIC bio has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IVERIC bio has recently increased by 14.49%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIVERIC bio does not currently pay a dividend.Dividend GrowthIVERIC bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ISEE. Previous Next 1.9 News and Social Media Coverage News SentimentIVERIC bio has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for IVERIC bio this week, compared to 4 articles on an average week.Search InterestOnly 11 people have searched for ISEE on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added IVERIC bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IVERIC bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,752,471.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of IVERIC bio is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IVERIC bio are expected to grow in the coming year, from ($1.76) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IVERIC bio is -21.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IVERIC bio is -21.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIVERIC bio has a P/B Ratio of 10.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IVERIC bio (NASDAQ:ISEE) StockIVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.Read More Receive ISEE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ISEE Stock News HeadlinesMay 31, 2023 | americanbankingnews.comIVERIC bio, Inc. (NASDAQ:ISEE) Short Interest UpdateMay 30, 2023 | seekingalpha.comIveric bio, Still A 5+% OpportunityMay 31, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.May 30, 2023 | finance.yahoo.comAnnexon (ANNX) Stock Down More Than 50% Last Week: Here's WhyMay 29, 2023 | americanbankingnews.comIVERIC bio (NASDAQ:ISEE) Coverage Initiated at StockNews.comMay 23, 2023 | seekingalpha.comBayer, Amgen looked at Iveric before agreeing to Astellas sale - reportMay 21, 2023 | americanbankingnews.comIVERIC bio (NASDAQ:ISEE) Research Coverage Started at StockNews.comMay 17, 2023 | msn.comUnusual Call Option Trade in IVERIC bio (ISEE) Worth $1,780.50KMay 31, 2023 | Edge On The Street (Ad)146 Pounds of Graphite Needed for Each EVGraphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.May 16, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for IVERIC bio, Inc. Issued By Wedbush (NASDAQ:ISEE)May 12, 2023 | americanbankingnews.comIVERIC bio (NASDAQ:ISEE) Earns Sell Rating from Analysts at StockNews.comMay 11, 2023 | americanbankingnews.comIVERIC bio, Inc. (NASDAQ:ISEE) Receives $19.00 Consensus Price Target from AnalystsMay 11, 2023 | fool.comIVERIC Bio (NASDAQ: ISEE)May 9, 2023 | msn.comTD Cowen Downgrades IVERIC bio (ISEE)May 6, 2023 | americanbankingnews.comIVERIC bio, Inc. (NASDAQ:ISEE) CFO Sells $2,352,040.00 in StockMay 5, 2023 | americanbankingnews.comIVERIC bio (NASDAQ:ISEE) Downgraded by Stifel NicolausMay 5, 2023 | americanbankingnews.comIVERIC bio, Inc. (NASDAQ:ISEE) Expected to Earn FY2027 Earnings of $1.46 Per ShareMay 4, 2023 | americanbankingnews.comIVERIC bio, Inc. (NASDAQ:ISEE) COO Keith Westby Sells 20,000 SharesMay 4, 2023 | americanbankingnews.comIVERIC bio (NASDAQ:ISEE) Cut to "Neutral" at Robert W. BairdMay 4, 2023 | americanbankingnews.comIVERIC bio (NASDAQ:ISEE) Downgraded by UBS Group to NeutralMay 4, 2023 | americanbankingnews.comMorgan Stanley Downgrades IVERIC bio (NASDAQ:ISEE) to Equal WeightMay 4, 2023 | americanbankingnews.comIVERIC bio (NASDAQ:ISEE) Rating Lowered to Neutral at HC WainwrightMay 3, 2023 | americanbankingnews.comWedbush Downgrades IVERIC bio (NASDAQ:ISEE) to NeutralMay 3, 2023 | americanbankingnews.comIVERIC bio (NASDAQ:ISEE) Rating Lowered to Neutral at Credit Suisse GroupMay 2, 2023 | marketwatch.comSHAREHOLDER ALERT: Weiss Law Investigates IVERIC bio, Inc.May 2, 2023 | benzinga.comMoore Kuehn Encourages ISEE, MDWT, CBOF, and SGEN Investors to Contact Law FirmMay 2, 2023 | americanbankingnews.comIVERIC bio (NASDAQ:ISEE) Downgraded by HC Wainwright to NeutralSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ISEE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ISEE Company Calendar Last Earnings3/01/2023Today5/31/2023Next Earnings (Estimated)7/25/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ISEE CUSIPN/A CIK1410939 Webivericbio.com Phone(609) 474-6755FaxN/AEmployees94Year FoundedN/APrice Target and Rating Average Stock Price Forecast$27.45 High Stock Price Forecast$35.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside-27.4%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-185,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.00% Return on Assets-46.15% Debt Debt-to-Equity Ratio0.20 Current Ratio15.53 Quick Ratio15.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.46 per share Price / Book10.92Miscellaneous Outstanding Shares137,780,000Free Float133,787,000Market Cap$5.21 billion OptionableOptionable Beta1.10 Key ExecutivesGlenn P. SblendorioChief Executive Officer & DirectorPravin U. DugelPresident & DirectorKeith WestbyChief Operating Officer & Senior Vice PresidentDavid F. CarrollChief Financial Officer, Treasurer & Senior VPEvelyn M. HarrisonChief Clinical Operations Officer & Senior VPKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLCerevel TherapeuticsNASDAQ:CEREAscendis Pharma A/SNASDAQ:ASNDOrganon & Co.NYSE:OGNAlkermesNASDAQ:ALKSView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,792 shares on 5/26/2023Ownership: 0.019%Ameriprise Financial Inc.Bought 150,021 shares on 5/22/2023Ownership: 0.902%Putnam Investments LLCBought 180,885 shares on 5/22/2023Ownership: 0.405%New York State Common Retirement FundSold 70,056 shares on 5/18/2023Ownership: 0.060%Gilder Gagnon Howe & Co. LLCSold 335 shares on 5/16/2023Ownership: 0.052%View All Insider TransactionsView All Institutional Transactions ISEE Stock - Frequently Asked Questions Should I buy or sell IVERIC bio stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ISEE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ISEE, but not buy additional shares or sell existing shares. View ISEE analyst ratings or view top-rated stocks. What is IVERIC bio's stock price forecast for 2023? 11 equities research analysts have issued 12-month price objectives for IVERIC bio's stock. Their ISEE share price forecasts range from $18.00 to $35.00. On average, they expect the company's stock price to reach $27.45 in the next twelve months. This suggests that the stock has a possible downside of 27.4%. View analysts price targets for ISEE or view top-rated stocks among Wall Street analysts. How have ISEE shares performed in 2023? IVERIC bio's stock was trading at $21.41 at the beginning of the year. Since then, ISEE stock has increased by 76.6% and is now trading at $37.80. View the best growth stocks for 2023 here. Are investors shorting IVERIC bio? IVERIC bio saw a increase in short interest in May. As of May 15th, there was short interest totaling 11,850,000 shares, an increase of 14.5% from the April 30th total of 10,350,000 shares. Based on an average trading volume of 3,750,000 shares, the short-interest ratio is currently 3.2 days. View IVERIC bio's Short Interest. When is IVERIC bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023. View our ISEE earnings forecast. How were IVERIC bio's earnings last quarter? IVERIC bio, Inc. (NASDAQ:ISEE) posted its quarterly earnings results on Wednesday, March, 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.10. During the same quarter in the previous year, the business posted ($0.29) EPS. What ETFs hold IVERIC bio's stock? ETFs with the largest weight of IVERIC bio (NASDAQ:ISEE) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), American Century Mid Cap Growth Impact (MID), Harbor Health Care ETF (MEDI) and Principal Healthcare Innovators ETF (BTEC). What is Glenn Spina's approval rating as IVERIC bio's CEO? 6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of IVERIC bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC). What is IVERIC bio's stock symbol? IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE." Who are IVERIC bio's major shareholders? IVERIC bio's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.39%), Price T Rowe Associates Inc. MD (4.97%), State Street Corp (4.08%), American Century Companies Inc. (2.95%), Braidwell LP (2.71%) and Geode Capital Management LLC (1.88%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel. View institutional ownership trends. How do I buy shares of IVERIC bio? Shares of ISEE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IVERIC bio's stock price today? One share of ISEE stock can currently be purchased for approximately $37.80. How much money does IVERIC bio make? IVERIC bio (NASDAQ:ISEE) has a market capitalization of $5.21 billion. The company earns $-185,210,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. How can I contact IVERIC bio? IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (609) 474-6755 or via email at kathy.galante@ivericbio.com. This page (NASDAQ:ISEE) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IVERIC bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.